• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circulation. Author manuscript; available in PMC Aug 5, 2013.
Published in final edited form as:
PMCID: PMC3733536
NIHMSID: NIHMS37707

Near-infrared fluorescent imaging of matrix metalloproteinase activity following myocardial infarction

Abstract

We used a molecular probe activated by protease cleavage to image expression of matrix metalloproteinases (MMPs) in the heart following myocardial infarction.

Methods and Results

We synthesized and characterized a near-infrared fluorescent (NIRF) probe that is activated by proteolytic cleavage by MMP2 and MMP9. The NIRF probe was injected into mice at various time-points up to 4 weeks after myocardial infarction induced by ligation of the left anterior descending artery. NIRF imaging of MMP activity increased in the infarct region with maximal expression at one to two weeks, persisting to four weeks. Zymography and real-time PCR analysis showed that MMP9 expression is increased at two to four days, while MMP2 expression is increased at one to two weeks. Dual label confocal microscopy showed colocalization of NIRF imaging with neutrophils on day 2, and flow cytometric analysis confirmed that NIRF signal is associated with leukocytes in the infarct zone.

Conclusion

This study demonstrates that the activity of MMPs in the myocardium may be imaged using specific activity-dependent molecular probes.

Keywords: matrix metalloproteinases, Myocardial infarction, Imaging, Gelatinase, Remodelling

Introduction

Myocardial infarction (MI) can lead to complex structural alterations in the heart, including dilation, contractile dysfunction and congestive heart failure1-4. Matrix metalloproteinases (MMPs) play important roles in the structural and functional sequelae of cardiac ischemia and infarction. In the heart, as in other tissues, MMPs participate in degradation of the extracellular matrix (ECM). In addition, MMPs have additional effects independent of ECM breakdown, including degradation of troponin I5, and modulation of platelet aggregation6,7 and vascular tone8,9.

The expression and activities of MMPs increase in the heart following MI10-13. Specifically, the gelatinases MMP2 and MMP9, and the tissue inhibitors of matrix metalloproteinases (TIMPs) have been implicated in the cardiac response to ischemia and infarction. Gene knockout of MMP214 or MMP915 decreases left ventricular remodeling and limits ventricular dilation after myocardial infarction. Loss of TIMP4 leads to enhanced MMP activity in the heart following ischemia16, and gene knockout of TIMP-1 exacerbates ventricular remodeling17. Pharmacologic blockade of MMP activity leads to decreased ventricular remodeling18-21.

Noninvasive methodology to optically image MMP activity would be of use to follow the temporal and spatial patterns of MMP activity after MI and in assessing treatment approaches. We hypothesized that we could monitor the myocardial remodeling process by imaging MMP activity. We used a novel, long-circulating, quenched NIRF probe that is activated by proteolytic cleavage22,23 by MMP2 and MMP9. Our studies indicate that specific molecular probes can be used to image MMP activity during left ventricular remodeling. This approach complements existing methods for following MMP levels and activity, such as zymography, immunohistochemistry, Western blotting, and scintigraphy24.

Methods

Myocardial infarction model

All procedures were approved by and performed in accordance with the IACUC of the Massachusetts General Hospital. Male C57BL6J mice, ranging in age from 8 to 12 weeks, weighing 25-30 g, underwent left anterior descending artery (LAD) ligation to induce MI25. Animals were anesthetized intraperitoneally with ketamine 0.065mg/g body weight, acepromazine 0.001 mg/g, and xylazine 0.013 mg/g. Animals were intubated and ventilated with a rodent respirator. After thoracotomy, the LAD was ligated with a 7-0 silk suture at a location 3-4 mm from the tip of the left atrium. Successful ligation of the LAD was verified by visual inspection of the left ventricular apex. The chest was closed with continuous 6-0 silk suture, and the skin was closed with 4-0 silk sutures. All mice were given water and food ad libitum.

MMP sensitive NIRF probe

The NIRF probe used in this study was synthesized using a previously published method26, except a peptide sequence recognized by MMP2 and MMP9 was used. This sequence, SGKGPRQITA, was identified by screening a phage library of random sequences using MMP9, and is cleaved between the Gln and Ile residues. It has a kcat/Km of 188,000 M−1s−1, which is 12 to 14 fold higher for MMP9 than for MMP-13 and MMP-727. This sequence was used with the linking residues GGPRQITAGK(Fitc)C to attach the fluorochrome Cy5.5 to a pegylated poly-L-lysine backbone.

Activation of the probe (0.2μM) was studied by incubating with 1 μg recombinant MMP9 or MMP2 (Oncogene) in 50 mM Tris HCl pH 7.5, 10 mM CaCl2, 100 mM NaCl and 0.005% Brij-35 at 37°C. The fluorescence signal changes were monitored at the specific excitation (675 nm) and emission (694 nm) maximum wavelengths of Cy5.5, using a fluorescence plate reader (SPECTRAmax Gemini, Molecular Devices, Sunnyvale, CA).

NIRF imaging

4 nmol NIRF probe was injected into the tail vein of mice 0 days, 2 days, 1 week, 2 weeks, 3 weeks and 4 weeks after myocardial infarction. This dose was chosen based on prior experience with other enzyme activatable probes in mice. The hearts were excised 48 hours later. NIRF imaging (2 minute acquisition) was performed using a 12-bit monochrome CCD camera (Kodak) equipped with an f/1.2 12.5-75 mm zoom lens and an emission long pass filter at 700 nm (Omega Optical). The NIRF signal was determined as mean signal intensities (SI) from either the infarct region or remote myocardium. Target-to-background ratios (TBR) were calculated as follows: TBR=SI(infarct area)/SI (remote area)28. All results are presented as mean ± SEM. Statistical analysis was conducted by using ANOVA, with values of P <0.05 being considered significant.

Left ventricular tissue extracts

Hearts were excised and washed in cold PBS. The infarct region and remote myocardium were separated under a dissecting microscope. Tissues were snap frozen in liquid nitrogen and homogenized in 0.5-1.0 ml of ice cold lysis buffer. The Western blot lysis buffer contained 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM PMSF, 5 ng/ml aprotinin, 5 ng/ml leupeptin, 1% Triton X-100, 1% sodium deoxycholate, and 1% SDS. The homogenates were centrifuged for 10 min at 4°C at 20,000g, and the supernatant was transferred to clean tubes. Protein concentration was determined by using a protein assay (Bio-Rad, CA) using bovine serum albumin as standards. The extracted samples were stored at −80°C until use.

Zymography

Protein samples containing 25 μg protein were adjusted to 40 μl, mixed with an equal volume of 2× loading buffer (126 mM Tris-HCl, 20% glycerol, 4% SDS, 0.05% bromophenol blue, pH 6.8), and incubated for 10 min at room temperature prior to loading to 10% gelatin-ready zymogram gel (Bio-Rad, 161-1167). 10 μl Precision protein standards (Bio Rad, 161-0372) were used as molecular weight standards, and 0.5 ng recombinant human MMP9 protein (Oncogene, PF024) and 0.5 ng purified MMP2 (Chemicon, cc071) were loaded as positive controls. Gels were run at 80 volts for 2 hours. The gels were incubated in 2.5% Triton X-100 for renaturation for 30 min. They were then equilibrated in fresh developing buffer (50 mM Tris-HCl,0.2 mM NaCl, 5 mM CaCl2, 0.02% Brij 35) and incubated at 37 °C overnight. Gels were stained with 0.5% Coomassie Blue G (40% methanol, 10% acetic acid) for 2 hours and destained with methanol:acetic acid:water (5:1:4) for 30 min. Areas of protease activity appear as clear bands against a dark blue background where the protease has digested the gelatin substrate.

Quantitative RT-PCR

MMP9 and MMP2 mRNA levels were measured by quantitative real time PCR of cDNA29. Total RNA was extracted from infarct regions using Trizol (GIBCO-BRL) and reverse-transcribed to cDNA by using Superscript II RT (GIBCO-BRL) using oligo (dT) as primers. Real time PCR was performed using an ABI Prism 7000 Sequence Detection system using SYBR Green. Primers were designed using Primer Express software. The primers for beta actin were TGG AAT CCT GTG GCA TCC ATG AAA C (forward), and TAA AAC GCA GCT CAG TAA CAG TCC G (reverse). The primers for MMP2 were GAC ATA CAT CTT TGC AGG AGA CAA G (forward) and TCT GCG ATG AGC TTA GGG AAA (reverse). The primers for MMP9 were CCT GGA ACT CAC ACG ACA TCT TC (forward) and TGG AAA CTC ACA CGC CAG AA (reverse). For each primer set, a standard curve was generated between the threshold cycle number and cDNA concentration. MMP2 and MMP9 mRNA levels were expressed as a ratio normalized to beta actin. Melting curves of the PCR products and agarose gel electrophoresis confirmed the specificity of the reaction.

Histology and immunohistochemistry

8 μm frozen sections were used for histology (hematoxylin and eosin staining), or immunohistochemistry for MMP9 and markers for macrophage and neutrophils. The following antibodies were used: (1) mouse anti-human MMP9 IgG (1:100, Chemicon, MAB 13415); (2) rat anti-mouse Ly-6G (Gr-1) IgG-FITC (1:50, PharMingen, 553126); (3) rat anti-mouse Mac3 IgG-FITC (1:50, PharMingen, 01784D); (4) donkey anti-mouse IgG-texas Red (1:50, Jackson, 715-075-150). The staining procedures have been described in detail elsewhere30. Confocal imaging was performed by confocal microscope (Leica TCS NT4D) with the use of a BP530/30 filter for FITC and a LP590 filter for Texas red. When the FITC and Texas Red signals colocalize, a yellow signal is seen.

Flow cytometric analysis

Mice with infarcted hearts or control mice were injected with NIRF probe or vehicle control. 24 h following probe administration, animals were euthanized using CO2 asphyxiation and their hearts immediately excised and washed in Hank's Balanced salt solution (HBSS). Infarct and non-infarct heart tissues were separated. All tissues were then minced finely and digested in collagenase (Worthington Biochemical, Lakewood, NJ, 2 mg/ml (w/v) in HBSS) at 37°C for 45 min. The resulting cell suspensions were filtered through 100 um pore size filters, pelleted and resuspended in RPMI-1640 containing 5 % FCS. Cells were then stained with anti-mouse CD45-FITC conjugated antibody (BD Pharmingen, San Diego, CA). Each population was analyzed on a BDFACSCalibur flow cytometer for the presence of CD45 and the NIRF probe. A miminum of 10,000 cells per sample were analyzed.

Results

NIRF probe detects MMP2 and MMP9 activity

The NIRF probe used in this study was similar to those used previously for imaging other proteases22,26,31. The probe contains multiple NIR fluorescent Cy5.5 dye molecules attached to the recognition peptide sequence which is positioned on a pegylated poly-L-lysine backbone. In the intact probe, the Cy5.5 molecules are in close proximity, and fluorescence resonance energy transfer results in efficient quenching. In the presence of MMP2 or MMP9, the peptide sequence is cleaved, resulting in liberation of the Cy5.5 dye molecules from the probe.

We tested the activation of the NIRF probe by MMP2 and MMP9 (Figure 1). At zero timepoint, there was only background fluorescence activity. Both MMP2 and MMP9 caused time-dependent increases in fluorescence, with roughly equivalent kinetics. Overall, either protease resulted in 200-fold signal amplification. Therefore, the NIRF probe is equally sensitive to MMP2 and MMP9.

Figure 1
Activation of NIRF probe by MMP2 and MMP9

NIRF imaging after myocardial infarction

To image MMP2 and MMP9 activity in the heart following MI, we performed LAD ligation in mice, resulting in an apical infarct. Figure 2 shows the appearance of the heart two days and one week later. The area of infarction is pale compared to surrounding tissue. At one week, the left ventricular apex showed thinning. The MMP2 and MMP9 sensitive probe was injected and NIRF imaging was performed. In the control animal, infarcted area had similar signal as normal tissue, with a target to background ratio (TBR) of 1.08±0.11. In animals receiving the probe, the TBR increased to 3.34±0.43 one week after MI, and areas of infarction were intensely bright (Figure 2).

Figure 2
NIRF imaging of MMP activated probe in the mouse heart after MI. Top row, probe was injected at the time of MI and imaged at 2 days. Bottom row, probe was injected at 5 days and imaged at 7 days. Left column, brightfield photograph; middle column, NIFR ...

We imaged MMP2 and MMP9 activity in different cohorts of animals to establish a time course over a four week period. The NIRF signal in the infarct zone rises and peaks at one to two weeks after myocardial infarction (Figure 3). It then decreases over time, but was still significantly elevated at 4 weeks compared to baseline values, or values from remote myocardium. Quantitation of the absolute NIRF signal, as well as the ratio of the signal between the infarct zone and a remote area, shows the same pattern.

Figure 3
Time course of MIRF signal following MI. A. NIRF signal intensity in infarct region (closed circles) and remote myocardium (open circles) is shown over time. Error bars show SEM.

MMP9 and MMP2 levels in the myocardium post MI

To correlate the NIRF imaging results with expression of MMP2 and MMP9, we performed zymography and quantitative RT-PCR analysis. Zymography showed that MMP9 activity is increased in the infarct zone at two and four days post-MI, with levels dropping subsequently (Figure 4). Of interest, MMP9 activity is increased in the remote area as well at four days, though less than in the infarct zone. In the infarct region, MMP2 activity increases by one week and reaches a maximum at two and three weeks. MMP2 activity is present in the remote area at low, but detectable levels. Multiple molecular species are seen for MMP9 and MMP2.

Figure 4
Zymography of MMP2 and MMP9 activity in heart following MI. A. Infarct zone. B. Remote zone. Gelatin in the polyacrylamide gel is hydrolyzed by MMP2 and MMP9 activity, resulting in clear bands.

We used real time PCR analysis of cDNA reverse transcribed from cardiac mRNA to quantitate MMP2 and MMP9 expression (Figure 5). In the infarct region, MMP9 mRNA levels were highest at two and four days post-MI, and decreased subsequently. MMP2 levels, in contrast, rose by four days, peaked at one to two weeks post-MI, and were still significantly increased at 4 weeks. Taken together, zymography and real-time PCR results were in agreement that MMP9 levels were increased at one and three days post-MI, and that MMP2 levels increased at one to four weeks.

Figure 5Figure 5
Real time PCR analysis of MMP2 and MMP9 mRNA levels in infarct regions following MI. RNA levels are expressed as a ratio normalized to beta-actin mRNA.

MMP9 is leukocyte-derived in the infarcted myocardium

Comparison of microscopic NIRF imaging with hematoxylin and eosin staining of an adjacent section shows that the fluorescence signal correlates with regions of leukocyte infiltration (Figure 6). Confocal microscopy with dual labeling for cell-specific markers and for MMP9 confirmed colocalization of MMP9 with a neutrophil marker at 1 day (Figure 7). To verify that MMP9 was leukocyte-derived in the infarcted myocardium, we made use of the NIRF probe to perform flow cytometric analysis on cells isolated from the heart. We used NIRF to detect the gelatinase probe, and immunoreactivity to the leukocyte common antigen CD45 to detect leukocytes. In the non-infarcted heart tissue, the majority of cells that display NIR fluorescence are CD45 negative. In the infarct region however, there is an increase in the number of CD45 positive cells that display NIR fluorescence (Figure 8). These results confirm our macroscopic observations and point to infiltrating leukocytes as the main source of the increase in MMP9 activity following myocardial infarction.

Figure 6
Microscopic NIRF imaging
Figure 7
Dual label confocal staining for MMP9, macrophages, and neutrophils, MMP9 is stained with Texas Red, while macrophages (top row) and neutrophils (bottom row) are stained with FITC conjugated antibody. MMP9 activity colocalizes strongly with neutrophils ...
Figure 8
Flow cytometry of gelatinase probe activation and CD45, Infarcted and non-infarcted regions of the heart were dissected, minced, and digested with collagenase. Cells were stained with CD45-FITC conjugated antibody, and analyzed for CD45 and the NIRF signal ...

Discussion

The MMPs are a family of Zn containing metalloproteinases that play important roles in ECM degradation32. MMPs have been divided into subgroups based on substrate specificity and domain structure33. MMP2 and MMP9 are of particular interest because they break down collagen, elastin, and basement membrane components. They share a common domain structure that includes type II fibronectin like domains, differentiating them from other MMPs34. Both MMP2 and MMP9 also have effects that appear to be independent of ECM breakdown. MMP2 degrades troponin I, a mechanism important to its effects on the heart following ischemia5. Other MMP targets affect vascular tone8,9 and platelet aggregation6.

Several lines of evidence point to the importance of MMP2 and MMP9 in cardiac remodeling after MI10-13, as well as in vascular remodeling following injury and during atherogenesis32,35. Gene knockout of either MMP214 or MMP915 results in attenuation of LV dilation following MI. Similarly, gene knockout of the MMP inhibitor TIMP-1 worsens ventricular dilation and remodeling after MI. Furthermore, pharmacologic blockade of MMP activity results in attenuation of ventricular dilation18-21.

Our results indicate that MMP9 and MMP2 activity show different time courses after MI. MMP9 increases by days 2 to 4, while MMP2 activity increases between 1 and 2 weeks. Other studies show similar time courses for MMP2 and MMP9 following MI36. Despite their shared substrate, MMP2 and MMP9 may play distinct roles following tissue injury, as shown in vascular remodeling32,35. In terms of cellular source, early after MI, NIRF activity colocalizes with areas of leukocytic infiltrate (Figure 6), and with neutrophils (Figure 7). Flow cytometry confirms that CD45-positive leukocytes account for the increase in NIR fluorescent cells in the heart following MI (Figure 8). These results indicate that infiltrating neutrophils are the likely cellular source of MMP9 activity early after MI.

Monitoring of MMP activity is complicated by overlapping substrate specificities of the MMPs, the fact that there are multiple species including proMMP zymogens, and multiple levels of regulation by TIMPs and other MMP inhibitors37. In addition, a recent report demonstrates that MMPs can be activated by S-glutathiolation in the presence of peroxynitrite38. Here, we show that an optically detectable probe that is activated by MMP2 and MMP9 can be used to image the activities of these proteases in the heart following MI. The use of such enzyme-activated probes would allow monitoring of the spatial and temporal patterns of MMP activity over time in the heart, and may facilitate the study of cardiac remodeling. They also provide a high degree of molecular specificity, as their fluorescence is based on activation by enzyme activity. However, the NIRF probe described here, like gelatin zymography, does not distinguish between MMP2 and MMP9.

In summary, we have shown that enzyme-activated NIRF probes can be used to image MMP activity in the myocardium following MI, providing both spatial and temporal information on activity. These probes may be useful to complement other techniques used to study MMPs, including zymography and scintigraphy24. Our results also indicate that these probes can be used to monitor enzyme activity on a microscopic level, and be coupled with flow cytometry. Similar NIRF probes have been coupled with optical tomography methods for in vivo imaging28,39.

Acknowledgments

This work was supported by PHS grants HL52818 to PLH and CA86355 to RW.

References

1. Bayat H, Swaney JS, Ander AN, Dalton N, Kennedy BP, Hammond HK, Roth DM. Progressive heart failure after myocardial infarction in mice. Basic Res Cardiol. 2002;97:206–13. [PubMed]
2. Weisman HF, Bush DE, Mannisi JA, Weisfeldt ML, Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation. 1988;78:186–201. [PubMed]
3. Patten RD, Aronovitz MJ, Deras-Mejia L, Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME, Konstam MA. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol. 1998;274:H1812–20. [PubMed]
4. Yang F, Liu YH, Yang XP, Xu J, Kapke A, Carretero OA. Myocardial infarction and cardiac remodelling in mice. Exp Physiol. 2002;87:547–55. [PubMed]
5. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106:1543–9. [PubMed]
6. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997;386:616–9. [PubMed]
7. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW, Davidge ST. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost. 1999;82:1730–5. [PubMed]
8. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res. 2000;87:670–6. [PubMed]
9. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906–11. [PubMed]
10. Lu L, Gunja-Smith Z, Woessner JF, Ursell PC, Nissen T, Galardy RE, Xu Y, Zhu P, Schwartz GG. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol. 2000;279:H601–9. [PubMed]
11. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520–30. [PubMed]
12. Danielsen CC, Wiggers H, Andersen HR. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol. 1998;30:1431–42. [PubMed]
13. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res. 2000;46:225–38. [PubMed]
14. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;285:H1229–35. [PubMed]
15. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55–62. [PMC free article] [PubMed]
16. Schulze CJ, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia-reperfusion injury. Circulation. 2003;107:2487–92. [PubMed]
17. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FG. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol. 2000;32:109–20. [PubMed]
18. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 2002;105:753–8. [PubMed]
19. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107:618–25. [PubMed]
20. Yarbrough WM, Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Escobar GP, Joffs C, Lucas DG, Crawford FA, Jr, Spinale FG. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003;125:602–10. [PubMed]
21. Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, Hendrick JW, Dowdy KB, McLean JE, Lowry AS, O'Neill TP, Spinale FG. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003;108:1753–9. [PubMed]
22. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001;7:743–8. [PubMed]
23. Bremer C, Tung CH, Weissleder R. Molecular imaging of MMP expression and therapeutic MMP inhibition. Acad Radiol. 2002;9(2):S314–5. [PubMed]
24. Schafers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schafers KP, Law MP, Schober O, Levkau B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2004;109:2554–9. [PubMed]
25. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995;269:H2147–54. [PubMed]
26. Law B, Curino A, Bugge TH, Weissleder R, Tung CH. Design, synthesis and characterization of urokinase-type plasminogen activator sensitive near-infrared reporter. Chem Biology. 2004;11:99–106. [PubMed]
27. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem. 2001;276:20572–8. [PubMed]
28. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002;105:2766–71. [PubMed]
29. Ishihara Y, Nishikawa T, Iijima H, Matsunaga K. Expression of matrix metalloproteinase, tissue inhibitors of metalloproteinase and adhesion molecules in silicotic mice with lung tumor metastasis. Toxicol Lett. 2003;142:71–5. [PubMed]
30. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol. 2003;23:97–103. [PubMed]
31. Tung CH, Bredow S, Mahmood U, Weissleder R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug Chem. 1999;10:892–6. [PubMed]
32. Whatling C, McPheat W, Hurt-Camejo E. Matrix management: assigning different roles for MMP-2 and MMP-9 in vascular remodeling. Arterioscler Thromb Vasc Biol. 2004;24:10–1. [PubMed]
33. Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002;8:S332–8. [PubMed]
34. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200:448–64. [PubMed]
35. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol. 2004;24:54–60. [PubMed]
36. Tao ZY, Cavasin MA, Yang F, Liu YH, Yang XP. Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice. Life Sci. 2004;74:1561–72. [PubMed]
37. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–39. [PubMed]
38. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem. 2001;276:29596–602. [PubMed]
39. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med. 2002;8:757–60. [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...